US Patent Issued on June 24 for "Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors to reduce detrimental effects of perfusion deficiency of parenchymal organs" (Wisconsin Inventor)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,337,001, issued on June 24.

"Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors to reduce detrimental effects of perfusion deficiency of parenchymal organs" was invented by Christopher Turski (Waunakee, Wis.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical composition...